论文部分内容阅读
作者用生物测定法对33个正常人、用I~(131)治疗前后的112例甲亢病人和27例垂体功能减退的病人测定了血清中的长效甲状腺刺激素(LATS)水平。正常人上限为179％,180～199％为可疑范围,超过200％为LATS阳性。结果在未经治疗的甲亢病人中仅27.7％血清中LATS水平升高或属可疑。在用I~(131)治疗后,血清中LATS滴度变化可分为4组:①42例治疗前后血清LATS水平均在正常范围或仅有一次属可疑;②9例开初的LATS滴度高,治后降为正常,其中4例仍
The authors used bioassays to measure long-acting thyroid-stimulating hormone (LATS) levels in 33 normal individuals, 112 patients with hyperthyroidism before and after treatment with 131, and 27 patients with hypopituitarism. Normal upper limit of 179%, 180 ~ 199% of the suspicious range, more than 200% positive for LATS. As a result, only 27.7% of patients with untreated hyperthyroidism had elevated serum LATS levels or were suspicious. After I ~ (131) treatment, the changes of serum LATS titer can be divided into four groups: ①42 cases of serum LATS levels before and after treatment in the normal range or only once is suspicious; ② 9 cases of early LATS titers, After treatment reduced to normal, of which 4 cases still